Outcome and subgroup | Studies | CR OXY events/total (%) | Comparison events/total (%) | Risk ratio (95% CI) | I2 (%) |
Any adverse event | |||||
CR OXY versus CR MOR | 3 | 142/196 (72.4) | 152/203 (74.9) | 0.97 (0.87 to 1.09) | 53 |
Asthenia | |||||
CR OXY versus IR OXY | 2 | 5/102 (4.9) | 9/106 (8.5) | 0.58 (0.2 to 1.68) | 30 |
Confusion | |||||
CR OXY versus IR OXY | 2 | 3/78 (3.8) | 4/79 (5.1) | 0.78 (0.2 to 3.02) | 25 |
CR OXY versus CR MOR | 3 | 74/295 (25.1) | 73/289 (25.3) | 1.01 (0.78 to 1.31) | 16 |
Constipation | |||||
CR OXY versus IR OXY | 3 | 25/156 (16) | 36/161 (22.4) | 0.71 (0.45 to 1.13) | 38 |
CR OXY versus CR MOR | 5 | 139/400 (34.8) | 141/397 (35.5) | 0.98 (0.82 to 1.16) | 33 |
CR OXY versus TD FEN | 2 | 88/171 (51.5) | 80/165 (48.5) | 1.07 (0.88 to 1.32) | 83 |
Dizziness/lightheadedness | |||||
CR OXY versus IR OXY | 3 | 15/156 (9.6) | 21/161 (13) | 0.74 (0.4 to 1.37) | 15 |
CR OXY versus CR MOR | 3 | 9/186 (4.8) | 12/181 (6.6) | 0.76 (0.33 to 1.76) | 0 |
Drowsiness/somnolence | |||||
CR OXY versus IR OXY | 3 | 36/156 (23.1) | 36/161 (22.4) | 1.03 (0.69 to 1.54) | 0 |
CR OXY versus CR MOR | 5 | 121/400 (30.3) | 134/398 (33.7) | 0.9 (0.75 to 1.08) | 0 |
Dry mouth | |||||
CR OXY versus IR OXY | 3 | 10/156 (6.4) | 9/161 (5.6) | 1.14 (0.48 to 2.75) | 0 |
CR OXY versus CR MOR | 4 | 89/343 (25.9) | 89/341 (26.1) | 1.01 (0.8 to 1.26) | 32 |
Dysuria | |||||
CR OXY versus CR MOR | 2 | 17/186 (9.1) | 24/186 (12.9) | 0.71 (0.4 to 1.26) | 0 |
CR OXY versus TD FEN | 2 | 19/171 (11.1) | 16/165 (9.7) | 1.15 (0.62 to 2.16) | 0 |
Hallucinations | |||||
CR OXY versus CR MOR | 4 | 14/349 (4) | 27/347 (7.8) | 0.52 (0.28 to 0.97) | 0 |
Headache | |||||
CR OXY versus IR OXY | 3 | 8/156 (5.1) | 10/161 (6.2) | 0.83 (0.34 to 2.02) | 61 |
Insomnia | |||||
CR OXY versus IR OXY | 2 | 5/132 (3.8) | 5/137 (3.6) | 1.04 (0.31 to 3.53) | 35 |
Nausea | |||||
CR OXY versus IR OXY | 3 | 32/156 (20.5) | 39/161 (24.2) | 0.85 (0.56 to 1.28) | 0 |
CR OXY versus CR MOR | 5 | 108/400 (27) | 106/398 (26.6) | 1.02 (0.82 to 1.26) | 0 |
Nervousness | |||||
CR OXY versus IR OXY | 2 | 5/102 (4.9) | 9/106 (8.5) | 0.57 (0.2 to 1.64) | 0 |
Pruritus | |||||
CR OXY versus IR OXY | 3 | 13/156 (8.3) | 9/161 (5.6) | 1.46 (0.65 to 3.25) | 33 |
CR OXY versus CR MOR | 4 | 29/343 (8.5) | 36/341 (10.6) | 0.81 (0.51 to 1.29) | 0 |
Sweating | |||||
CR OXY versus IR OXY | 2 | 5/132 (3.8) | 8/137 (5.8) | 0.65 (0.22 to 1.93) | 55 |
Vomiting | |||||
CR OXY versus IR OXY | 3 | 18/156 (11.5) | 28/161 (17.4) | 0.66 (0.38 to 1.15) | 18 |
CR OXY versus CR MOR | 5 | 60/400 (15) | 64/398 (16.1) | 0.94 (0.68 to 1.29) | 2 |
Discontinuation due to adverse events | |||||
CR OXY versus IR OXY | 3 | 11/156 (7.1) | 19/161 (11.8) | 0.6 (0.29 to 1.22) | 0 |
CR OXY versus CR MOR | 3 | 9/196 (4.6) | 9/203 (4.4) | 1.06 (0.43 to 2.6) | 48 |
CR, controlled release; FEN, fentanyl; IR, immediate release; MOR, morphine; OXY, oxycodone; TD, transdermal.